DUBLIN, Aug. 06, 2015 /PRNewswire/ --
Research and Markets(http://www.researchandmarkets.com/research/7pf46k/investigation) has announced the addition of the "Investigation Report on China's Liraglutide Market, 2011-2019" report to their offering.
As the economy develops and living standards improve, the Chinese people's dietary pattern changes, resulting in excess eating. Meanwhile, the drop in physical activities leads to the increased obesity rate. Other factors like the ageing population also play a role in the rapid increase of diabetes incidence in China.
Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, was developed by Novo Nordisk in 2008 to treat diabetes. Liraglutide, a derivative attained by attaching a fatty acid molecule to GLP-1 molecule, can reduce the HbA1c level and weight of type 2 diabetes mellitus (T2DM) patients and improve the function of beta cells. Since it stimulates insulin secretion and inhibits glucagon secretion only when blood glucose levels are higher than normal, it shows negligible risk of hypoglycemia. On January 25th 2010, liraglutide was approved by FDA to be used as the second-line drug alone or together with other oral antidiabetic drugs for the treatment of T2DM. In 2013, the sales value of liraglutide around the world exceeded USD 2 billion.
After entering China in October 2011, liraglutide developed fast with annual sales value rising from less than CNY 0.5 million in 2011 to CNY 19.71 million in 2014 and CAGR reaching up to 246% during the period of 2011-2013. Currently, the liraglutide market in China is monopolized by Novo Nordisk. Although liraglutide, as an imported drug, is priced relatively high in China, it still has good market prospects.
Key Topics Covered:
1 Related Concepts of Liraglutide
2 Market Profile of Liraglutide in China
3 Survey on Sales Status of Liraglutide in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Liraglutide in China, 2010-2014
5 Survey on Dosage Forms of Liraglutide in China, 2010-2014
6 Reference Price of Liraglutide in Chinese Hospitals in 2014
8 Market Outlook of Liraglutide in China, 2015-2019
- Novo Nordisk
For more information visit http://www.researchandmarkets.com/research/7pf46k/investigation
Media Contact: Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets